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for gastric cardia adenocarcinoma and functionally
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Aiqin Sun1†, Guanzhen Yu2†, Xiaoyan Dou1, Xiaowei Yan3, Wannian Yang4* and Qiong Lin1,4*Abstract
Background: Gastric cardia adenocarcinoma (GCA) is the most aggressive subtype of gastric carcinoma. New
molecular markers and therapeutic targets are needed for diagnosis, prognosis and treatment of GCA. This study is
to establish the E3 ubiquitin ligase Nedd4-1 as a prognostic biomarker to predict the survival and guide the treatment
of GCA patients.
Methods: Expression of Nedd4-1 in 214 GCA tumor samples was detected by immunohistochemistry staining (IHC)
using tissue microarray assay (TMA). Association of Nedd4-1 with cumulative survival of the TNM stages I-III patients
and clinicopathological characteristics was statistically analyzed. The role of Nedd4-1 in gastric cancer cell migration
and invasion were determined by transwell and wound healing assays.
Results: Nedd4-1 is overexpressed in 83% of the GCA tumors. The 5-year survival rate in Nedd4-1 negative GCA
patients is as high as 96%. Log-rank analysis indicated that overexpression of Nedd4-1 is inversely correlated
with cumulative survival (χ2 = 21.885, p <0.001). Multivariate logistic regression analysis showed that overexpression
of Nedd4-1 is associated with an extremely low GCA survival rate with a hazard ratio (HR) = 0.068 (p = 0.008) in TNM
stages I-III patients. Statistical analysis of association of Nedd4-1 overexpression with clinicopathological characteristics
revealed that overexpression of Nedd4-1 is tightly associated with TNM stage (p < 0.001). Knockdown of Nedd4-1 in
gastric cancer cell lines AGS and N87 dramatically inhibited the gastric cancer cell migration and invasion.
Conclusions: Our results indicate that Nedd4-1 is an exceptional prognostic biomarker for GCA and suggest that
Nedd4-1 may play an essential role in GCA metastasis.
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Gastric cancer was the fifth most common cancer and
one of the highest mortality cancer types. Gastric cardia
adenocarcinoma (GCA), a sub-type of adenocarcinoma
of esophagogastric junction (AEJ) localized about 2 cen-
timeters below esophagogastric junction (gastric cardia),
is the most aggressive type of gastric carcinoma [1-3].
Incidents of GCA in Asia have been increasing in recent
years. Currently, surgery is still the major therapeutic
means for GCA patients. There has been no effective* Correspondence: wyang1@geisinger.edu; qlin1@geisinger.edu
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surgery recurrence rates in GCA are as high as 40-65%
[4]. How to effectively treat GCA is a big challenge faced
in gastric cancer therapy.
Metastasis and post-surgery recurrence are the major
causes for poor prognosis in GCA. Thus, treatment of
metastasized and post-surgery GCA patients is crucial
for improving therapeutic outcome and increasing GCA
survival rate. There are a few molecular biomarkers of
GCA, such as Sirt1, ErbB2, MCM2, identified in recent
years [5-7]. Very recently, Nedd9, a Crk-associated pro-
tein involved in focal adhesion, has been found overex-
pressed in gastric cancer [8-10]. Expression of Nedd9 is
tightly associated with gastric cancer progression, particu-
larly metastasis. Thus, Nedd9 is proposed as a prognostic. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Pathological information of gastric cardia
adenocarcinoma samples
Pathological category Case number % of total cases
Age < = 60 108 50.5
>60 106 49.5
Gender Male 157 73.4
Female 57 26.6
Tumor size < = 6 cm 166 77.6
>6 cm 48 22.4
T category T1/T2 63 29.4
T3/T4 151 70.6
N category N0 73 34.1
N1-3 141 65.9
Differentiation Well/Moderately 130 60.7
Poorly/undiff 84 39.3
TNM-stage I/II 83 38.8
III/IV 131 61.2
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Nedd9 in GCA is not known. Currently, none of the bio-
markers has been used for diagnosis and prognosis or as
therapeutic targets for GCA, or guiding the post-surgery
treatment and targeted therapy. The EGFR inhibitor Erlo-
tinib was applied for, but failed in phase II clinical trial of
the targeted therapy in GCA [11]. Molecular events of
carcinogenesis and metastasis in GCA are still poorly
understood. New molecular markers and therapeutic tar-
gets are needed for diagnosis, prognosis and treatment of
GCA.
Nedd4-1 is a member of the HECT domain-containing
E3 ubiquitin ligase family. The cellular function of Nedd4
was initially found in regulation of degradation of epithe-
lial sodium channel (ENaC) [12]. Defect in ubiquitination
of ENaC by Nedd4 causes hypertension named Liddle
Syndrome [13]. Nedd4-1 is involved in regulation of many
intracellular signaling molecules, endocytic or vesicle sort-
ing proteins, such as Cbl, Eps15, Tsg101, Hrs, SCAMPs,
and ACK1 [14-20]. Knockdown of Nedd4-1 in A549 cells
inhibited ligand-induced degradation of EGFR and signifi-
cantly elevated expression level of EGFR [20].
The role of Nedd4-1 in tumorigenesis has been brought
to attention in recent years. Nedd4-1 has been shown to
interact with, ubiquitinate and down-regulate the tumor
suppressor pTEN, and proposed as a pro-oncogenic pro-
tein [21]. Immunohistochemical (IHC) staining studies
observed that Nedd4-1 is overexpressed in lung, colon
and breast tumors [22-24]. These studies suggest that
Nedd4-1 may play an important role in carcinogenesis.
Expression of Nedd4-1 in gastric tumor has been investi-
gated, however, the results were inconsistent [25,26]. In
addition, no correlation of Nedd4-1 expression with clini-
copathological categories has been found in gastric cancer
[26]. Down-regulation of the tumor suppressor pTEN is
in general thought to be the molecular mechanism under-
lying Nedd4-1-associated oncogenesis [22-24]. However,
there is still a debate on pTEN as an ubiquitination sub-
strate of Nedd4-1 and a cause for Nedd4-1-associated
oncogenesis [27-29]. A recent study found that Nedd4-1
down-regulates Lats1, a serine/threonine kinase in the
Hippo pathway, suggesting that Nedd4-1 may activate
YAP/TAZ signaling for promoting oncogenesis [30].
Given that Nedd4-1 is an important pro-oncogenic pro-
tein and little is known about its functional association
with clinicopathological characteristics of tumors, we at-
tempt to further define the role of Nedd4-1 in tumor gen-
esis and progression at a clinical setting. In this report, we
detected expression of Nedd4-1 in 214 GCA tumor sam-
ples with immunohistochemical (IHC) staining and found
that Nedd4-1 overexpressed in 83% of GCA tumors. The
Nedd4-1 negative GCA patients in TNM stage II/III had
100% of 5-year survival rate, suggesting that Nedd4-
negative staining could be used for prediction of survivalin GCA. On the other hand, overexpression of Nedd4-1 in
GCA is inversely associated with survival and tightly cor-
related with metastasis of GCA. Furthermore, we have
shown that depletion of Nedd4-1 by shRNA in gastric
cancer cells impairs both the basal and EGF-stimulated
cell migration and invasion, indicating that Nedd4-1 plays
a “driver” role in metastasis of GCA. Our studies for the
first time demonstrate that Nedd4-1 is an exceptional bio-
marker for prognosis of GCA. The functional association
of Nedd4-1 with GCA metastasis suggests Nedd4-1 as a
potential anti-metastatic drug target for GCA therapy.
Results
Clinicopathological information of the GCA tumor
samples used for IHC staining of Nedd4-1
Total 214 GCA tumor samples were collected. The clini-
copathological information is listed in Table 1. In this
GCA patient population, the occurring frequency of
GCA in or below and above age 60 is almost even (108
for < = 60 year-old, and 106 for >60 year-old). Roughly
three quarters of the patients were male. More than
three quarters of tumors were equal to or smaller than
6 centimeters. About two thirds of the patients were
diagnosed with the tumors highly invaded (T3/T4) or
metastasized to lymph nodes (N1-3 categories) or at
advanced TNM stages (stage III/IV).
The post-surgery survival rate of the GCA patients
was followed and censored. Overall mean survival time
of the patients is 64.036 ± 3.554 months (95% confiden-
tial interval (CI): 57.070 – 71.002). Association of the
pathological categories with cumulative survival is dis-
played by Kaplan-Meier survival graph and statistically
analyzed by log-rank test (Figure 1). The mean survival
Figure 1 Association of pathological characteristics with cumulative survival in GCA patients. Association of tumor size, invasion (T category),
lymph node metastasis (N category), differentiation, and TNM stages with cumulative survival of GCA patients is shown in Kaplan-Meier survival graphs.
The Chi-square and p values from Mantel-Cox test and the mean survival for each pathological category are shown in the figure.
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shown in Figure 1. The data have shown that differences
between tumor sizes, invasive degrees (T categories),
lympho node metastasis (N categories), grades (differ-
entiation) and TNM (T category, N category and remote
metastasis) stages are all significantly and inversely associ-
ated with patient survival (p = 0.003 or <0.001). The
chi-square values from log-rank test indicate that differ-
ence in cumulative survival between the TNM-stages is
the most significant, followed by tumor sizes and grades
(Figure 1). In categories of TNM stage, N category is more
significant than T category. These data suggest that tumor
metastasis might be the major factor related to mortality
of the GCA patients.
Nedd4-1 is tightly associated with poor prognosis of
gastric cardia adenocarcinoma
The E3 ubiquitin ligase Nedd4-1 has been identified as a
pro-oncogenic protein and is overexpressed in lung, colon
and breast cancers [20-23]. To detect Nedd4-1 in GCA,
we raised an anti-Nedd4-1 antibody in rabbits usingGST-human Nedd4-1 fusion protein as an antigen. As
shown in the figures in Additional file 1, this anti-
Nedd4-1 antibody recognizes both ectopically and en-
dogenously expressed Nedd4-1 in immunoblotting and
immunofluorescent staining, indicating that this anti-
Nedd4-1 is highly specific and able to detect Nedd4-1
in both denaturing and non-denaturing conditions.
The expression of Nedd4-1 in the 214 GCA tumors
and their adjacent normal tissues was then examined
by theTMA assay with IHC staining. As shown in Figure 2A,
expression of Nedd4-1 in the GCA tumors is significant
higher than in their adjacent normal tissues (p < 0.0001).
The TMA assay has shown that 177 of the 214 GCA tumors
(83%) were strongly stained with anti-Nedd4-1, and only 37
tumor samples (17%) had weak or no staining (Figure 2B),
indicating that Nedd4-1 is overexpressed in GCA with a very
high frequency.
To assess the role of Nedd4-1 in prognosis, we de-
termined association of Nedd4-1 expression with cu-
mulative survival of the GCA patients in TNM stages





Figure 2 Nedd4-1 is overexpressed in GCA and the overexpression is tightly negatively correlated with cumulative survival of GCA
patients. A, Overexpression of Nedd4-1 in GCA tumor tissue is significantly higher than in their adjacent normal gastric cardia tissue. The average
scores and standard deviations of IHC staining of Nedd4-1 in both GCA tumors (T) and their adjacent normal tissue (N) are shown in the figure.
B, IHC staining of Nedd4-1 in GCA tumor samples. C, Kaplan-Meier survival curve of Nedd4-1 positive and negative GCA patients in TNM
stages I-III. The Chi-square and p values from Mantel-Cox test and the mean survival for Nedd4-1 negative and positive GCA of TNM stages
I-III are shown in the figure. D. Kaplan-Meier survival curve of Nedd4-1 positive and negative GCA patients in each of TNM stages. The p value
was calculated from Mantel-Cox test.
Sun et al. Molecular Cancer 2014, 13:248 Page 4 of 10
http://www.molecular-cancer.com/content/13/1/248Kaplan-Meier survival graph (Figure 2C), the patients
with the Nedd4-1 negative tumor had average cumulative
survival of 106.421 ± 2.535 months during the follow-up.
The 5 year survival rate in the Nedd4-1 negative GCA pa-
tients is estimated as high as 96%. On the other hand, the
Nedd4-1 positive patients had average cumulative survival
of 59.963 ± 4.303 months (Figure 2C). The 5 year survival
rate in the Nedd4-1 positive patients is estimated as 45%,
significantly lower than that of the Nedd4-1 negative
patients. Difference between the Nedd4-1 positive and
negative patient’s cumulative survival is determined by
log-rank test (Figure 2C). The chi-square value is 21.885
with p < 0.001, indicating that cumulative survival between
the Nedd4-1 positive and the negative patients is dramat-
ically different and that Nedd4-1 expression is inversely
associated with post-surgery survival in TNM stages I-III
patients.Association of Nedd4-1 expression with cumulative
survival in each of TNM stages was further analyzed
with Kaplan-Meier graphs (Figure 2D). The data have
shown that overexpression of Nedd4-1was significantly
inversely associated with cumulative survival in TNM
stages II/III patients (p = 0.008 and 0.019 respectively),
but not associated with the cumulative survival in
TNM stage I GCA patients (p = 0.573). The graphs in
Figure 2D clearly show that all the Nedd4-1 negative
GCA patients in TNM stages II/III were survived through-
out the follow-up, indicating that Nedd4-1 negative stain-
ing is an exceptional index for predicting survival of the
GCA patients diagnosed in TNM stages II/III. Because
Nedd4-1 expressed in almost all the collected tumors in
TNM stage IV patients, the Nedd4-1 negative staining as a
survival predictor cannot be evaluated in this group of
GCA patients.
Table 3 Association of Nedd4-1 expression with






Age < = 60 108 88 81.5 0.631
>60 106 89 84
Gender Male 157 128 81.5 0.448
Female 57 49 86
Tumor size <=6 cm 166 135 81.3 0.319
>6 cm 48 42 87.5
T category T1/T2 63 43 68.3 0.001
T3/T4 151 134 88.7
N category N0 73 50 68.5 < 0.001
N1-3 141 127 90.1
Differentiationa Well/Mod 130 103 79.2 0.066
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logical categories and expression of Nedd4-1 was further
analyzed using multivariate Cox regression model (Table 2).
The survival rate for Nedd4-1 overexpression is much
lower than other pathological categories (among TNM
stages I-IV patients, HR = 0.07 with 95% CI: 0.009-0.52;
among TNM stages I-III patients, HR = 0.068 with 95% CI:
0.009-0.495). Furthermore, TNM stage and N category are
significant factors inversely associated with the survival rate
(HR = 0.617, 95% CI: 0.382-0.998 for TNM stage, and
HR = 0.364, 95% CI: 0.15-0.88 for N category). The data
clearly indicate that Nedd4-1 overexpression is the best
predictor for poor prognosis of GCA, followed by N cat-
egory or TNM stage. As N category and TNM stage are
known to be positively correlated with metastasis, these
data suggest that metastasis is the key process in poor sur-
vival of GCA.Poor/Undiff 84 74 88.1
TNM stage I 44 28 63.6
II 39 28 71.8 I/II vs III/IV
III 98 89 90.8 <0.001
IV 33 32 97.0
aIn differentiation category, “Well” stands for well differentiated, “Mod” for
moderately differentiated, “Poor” for poorly differentiated, “Undiff”
for undifferentiated.Nedd4-1 is associated with metastasis of GCA
We further statistically analyzed correlation of Nedd4-1
overexpression with pathological characteristics in GCA
tumors. As shown in Table 3, Nedd4-1 overexpression is
tightly associated with TNM stages, N and T categories,
but not with age (p = 0.631), gender (p = 0.448), tumor
size (p = 0.319) or grade (differentiation) (p = 0.066). In
T category, 88.7% of the T3/T4 GCA patients were
Nedd4-1 positive, compared to 68.3% of the T1/T2 pa-
tients (p = 0.001). In N category, Nedd4-1 positive stain-
ing is observed in 90.1% of N1-3 GCA patients (spread
to regional lymph nodes), versus 68.5% for no lymph
node spreading (p <0.001). In TNM stages, Nedd4-1
positive staining is observed in 97% of stage IV patients
who had distant site metastasis and 90.8% of stage III
patients who had severe lymph node metastasis, com-
pared to 63.6% of stage I patients and 71.8% of stage II
patients who had no or minor lymph node metastasis.Table 2 Multivariate Cox regression analysis of
correlation of clinicopathological characteristics and
Nedd4-1 with AGC cumulative survival
Category Hazard ratio P
(95% CI)
TNM stage 0.617 (0.382-0.998) 0.049
T category 0.513 (0.211-1.246) 0.140
N category 0.364 (0.150-0.882) 0.025
Differentiation 0.819 (0.521-1.288) 0.388
Tumor size 0.932 (0.317-2.739) 0.899
Nedd4-1a 0.070 (0.009-0.521) 0.009
Nedd4-1b 0.068 (0.009-0.495) 0.008
aTNM stage IV samples were included in the analysis.
bTNM stage IV samples were excluded in the analysis.
TNM stage IV samples were included in the analysis of all other
pathological categories.The data in Table 3 strongly suggest that Nedd4-1 plays
an important role in GCA progression and metastasis.
To verify the function of Nedd4-1 in GCA metastasis,
we used two gastric cancer cell lines N87 and AGS
[31,32] to determine the role of Nedd4-1 in promoting
cell migration and invasion, the two important cellular
processes in metastasis. N87 was derived from the liver
metastasis of a gastric cancer [31] and AGS was demon-
strated to be metastatic [33], and both cell lines were
used for cancer cell migration and invasion assays in
previous studies [34,35]. We first established the Nedd4-
1-knockdown cell lines in both AGS and N87 using
lentiviral vector-loaded Nedd4-1 shRNA. More than
90% of Nedd4-1 was depleted in the sh-Nedd4-1 cell
lines (Figure 3A). Depletion of Nedd4-1 inhibited cell
proliferation significantly in both AGS and N87 cells,
but less severely in N87 cells (Figure 3B). We then de-
termined effect of Nedd4-1 knockdown on cell migra-
tion and invasion in AGS cells and cell migration in
N87 cells. As shown in Figure 3C, depletion of Nedd4-
1 by the shRNA dramatically inhibited both basal and
EGF-promoted cell migration in both cell lines using
the wound healing assay. In the transwell invasion or
migration assay, the basal and EGF-promoted cell in-
vasion in AGS cells and migration in N87 cells were com-
pletely diminished by knockdown of Nedd4-1 (Figures 3D
and E). These results indicate that Nedd4-1 promotes
both basal and the EGF-promoted cell migration and
A B
C D E
Figure 3 Nedd4-1 is essential for gastric cancer cell invasion and migration. A, Nedd4-1 in gastric cancer AGS and N87 cells was depleted
by lentiviral vector-loaded Nedd4-1 shRNA. The gastric cancer cells were infected by lentiviral vector-loaded Nedd4-1 shRNA for 48 hours and
endogenous Nedd4-1 in the cell lysates was detected by immunoblotting with anti-Nedd4-1. B, The effect of Nedd4-1 knockdown on AGS
and N87 cell proliferation. C, The wound healing assay of the effect of Nedd4-1 knockdown on the gastric cancer cell migration. D, The invasion
of AGS cells was determined by the transwell matrigel invasion assay. E, The migration of N87 cells was detected by the Transwell migration assay. The
gastric cancer cell proliferation, migration and invasion assays were repeated three times and the results were consistent.
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studies from the IHC staining of GCA tumor tissues
and the cell invasion and migration assays of the
Nedd4-1-depleted AGS and N87 cells suggest that
Nedd4-1 is a crucial “driver” protein in metastasis of
GCA that is the major cause for GCA mortality.
Discussion
GCA is one of the most aggressive cancer types that
affect millions of people’s life and living quality world-
wide, particularly in Asia countries. Currently, no effect-
ive chemo or targeted therapeutic method has been
established for GCA patients. Elucidation of pathological
mechanisms and identification of diagnostic and prog-
nostic biomarkers and therapeutic targets are urgent
tasks for improving diagnosis and treatment of GCA.
Here we identified the HECT E3 ubiquitin ligase Nedd4-1
as a predictive biomarker of poor prognosis of GCA. IHC
staining of 214 GCA tumor samples has shown that
Nedd4-1 was overexpressed in 83% of GCA tumors. Stat-
istical analysis of the IHC staining data and the GCAtumor clinicopathological data found a very significant as-
sociation of Nedd4-1 negative GCA with the post-surgery
survival, especially in TNM stages II/III patients. The
pathological data of the 214 GCA tumor samples suggest
that metastasis is an important factor of poor prognosis.
Analysis of association of Nedd4-1 overexpression with
pathological categories has shown that Nedd4-1 overex-
pression is linked to GCA metastasis. The studies with
knockdown of Nedd4-1 in gastric cancer AGS and N87
cells demonstrated that Nedd4-1 has a major role in pro-
moting the gastric cancer cell invasion and migration, the
two key cellular processes in metastasis, and an effect on
the cell proliferation as well. Our work suggests that
Nedd4-1, as a predictive biomarker of poor prognosis of
GCA, functions in GCA progression, particularly in
metastasis.
Nedd4-1 is an HECT E3 ubiquitin ligase that is known
to ubiquitinate the tumor suppressor pTEN and causes
proteasomal degradation and nuclear translocation of
pTEN [21,36]. This activity of Nedd4-1 was proposed as
the pro-oncogenic role of Nedd4-1 [21,36]. However,
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Nedd4-1 in ubiquitination of pTEN for degradation and
nuclear translocation [27,28]. Nevertheless, overexpres-
sion of Nedd4-1 has been found in multiple types of tu-
mors by IHC staining [22-24]. A recent report claimed
that overexpression of Nedd4-1 in colon cancer tissues
was not correlated with down-regulation of pTEN [29],
suggesting that at least in some cases the function of
Nedd4-1 in oncogenesis or tumor progression may not
be dependent on down-regulation of pTEN. In our stud-
ies, the major role of Nedd4-1 seems promoting tumor
cell migration and correlated to GCA metastasis. It is
not clear whether Nedd4-1 promotes GCA metastasis
through down-regulation of pTEN. Multiple substrates
of Nedd4-1 in addition to pTEN have been identified.
These substrates include receptor or non-receptor tyro-
sine kinases, serine/threonine kinases and other signal-
ing molecules [14-20]. In addition, very recent studies
found that the Crk-associated focal adhesion protein
Nedd9 is overexpressed in gastric cancer and tightly as-
sociated with metastasis [8-10]. The functional resem-
blance of Nedd9 to Nedd4-1 in gastric cancer metastasis
may be yielded from a connected biochemical process.
Taken together, Nedd4-1 may promote GCA progression
and metastasis through complex signaling pathways.
Two research groups have investigated overexpression
of Nedd4-1 in gastric tumor tissues [25,26]. One group
observed no up-regulation of Nedd4-1 and no correl-
ation with pTEN expression in 50 gastric cancer tumor
samples [25]. The other found that Nedd4-1 was overex-
pressed in 75% of 60 gastric tumor samples, but ex-
pression of Nedd4-1 had no significant association with
clinicopathologic characteristics, including invasion, me-
tastasis and stage [26]. These results are inconsistent with
our studies in GCA. The discrepancy may be produced
from differences in gastric tumor types or tumor sample
numbers. GCA is a very unique type of gastric cancer that
has much higher mortality and poorer prognosis than
general gastric cancer due to its high invasive and meta-
static properties.
Our studies indicate that Nedd4-1 is an exceptional bio-
marker for predicting poor prognosis of the post-surgery
GCA. Thus, detection of overexpression of Nedd4-1 by
IHC in GCA tumors may be applied for GCA clinic and
used to guide GCA treatment. The Nedd4-1 negative
GCA patients should be treated differentially from the
Nedd4-1 positive GCA patients. As the Nedd4-1 negative
GCA patients in TNM stages II and III had as high as
100% of 5-year survival rate (Figure 2D), Nedd4-1 negative
staining could be used for prediction of GCA patient’s
post-surgery survival and guiding the post-surgery treat-
ment. In addition, pathological classification of the GCA
patients with Nedd4-1 IHC staining scores should be
established upon further investigation with more cases,and used for diagnosis of GCA in combination with
TNM-stage or T/N categories in clinic. Our studies also
suggest that Nedd4-1 is a new target molecule for anti-
cancer therapy of GCA as evidenced by its inverse associ-
ation with GCA patient survival and essential role in the
gastric cancer cell invasion and migration. Inhibition of
Nedd4-1 may be an efficient approach for blocking GCA
metastasis or relapse and improving survival rate of GCA
patients.
Our data for the first time show that Nedd4-1 pro-
motes gastric cancer cell invasion and migration and is
tightly associated with GCA metastasis. In particular,
Nedd4-1 mediates EGF-dependent gastric cancer cell in-
vasion and migration, suggesting that Nedd4-1 may par-
ticipate in EGFR-mediated tumor metastasis signaling. It
is known that EGFR signaling plays an important role in
cell migration and invasion in multiple types of cancer
[37-41]. Mutations of EGFR have been identified as a
key driving cause in tumorigenesis and progression of
non-small cell lung carcinoma (NSCLC) [42-44]. How
Nedd4-1 mediates EGFR cell migration and invasion
signaling in both GCA and NSCLC cells is an import-
ant question for understanding the role of Nedd4-1 in
tumor genesis and progression and needed to investi-
gate further.Conclusions
The E3 ubiquitin ligase Nedd4-1 is overexpressed in
83% of GCA tumors. The expression of Nedd4-1 is in-
versely associated with cumulative survival of GCA pa-
tients. Nedd4-1 negative GCA patients had a striking
high survival rate, suggesting that Nedd4-1 negative
staining could be used for prediction of post-surgery sur-
vival of GCA. Overexpression of Nedd4-1 is tightly asso-
ciated with TNM stage of GCA, and knockdown of
Nedd4-1 in gastric cancer cells dramatically reduces the
cell migration and invasion capability, indicating that
Nedd4-1 is functionally associated with GCA metastasis.
Our studies conclude that Nedd4-1 is an exceptional
prognostic biomarker for prediction of post-surgery sur-
vival and a potential anti-metastatic target in GCA therapy.Methods
Materials
Lentiviral human Nedd4-1 shRNA clones were purchased
from Open Biosystems. The mAb against the hemagglutinin
(HA) (12CA5) was purchased from Roche Applied Science.
The polyclonal anti-Nedd4-1 antibody was made by
injecting GST-human Nedd4-1 fusion protein into rab-
bits and purified by protein A beads. IHC staining S-P
kit (KIT-9710) was purchased from MAIXIN Biology
Corporation. The gastric cancer cell lines AGS and
N87 were purchased from ATCC.
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Tissue microarrays containing 214 cases with primary gastric
cardia adenocarcinoma were used for detection of Nedd4-1
expression, which were preserved in the Gastric Cancer
Tissue Bank at Department of Oncology, Changzheng
Hospital (Shanghai, China). All the cases received curative
resection. All of the tissue specimens for this study were
obtained with patient informed consent, and the use of
these GCA specimens was approved by the Changzheng
and Changhai Hospital Institutional Review Board.
Immunohistochemistry (IHC)
Standard procedure was performed to determine the
level of Nedd4-1 expression in the GCA tumor sam-
ples. Briefly, 4 μm sections of paraffin-embedded GCA
tissue microarrays were de-paraffinized and rehydrated
in xylene and alcohol bath solution. Antigen unmask-
ing was performed by pretreatment of the slides in
0.01 M citrate buffer (pH 6.0) at 98°C for 5 min using
a microwave oven. The slides were then cooled to
room temperature. Endogenous peroxidase was elimi-
nated by incubating the slides in 3% hydrogen peroxide
for 10 min. After washed in 10 mM PBS (pH 7.4), the
sections were incubated with normal goat serum at
room temperature for 10 min, followed by incubation
with anti-Nedd4-1 antibody (dilution: 1:100) at 4°C over-
night. An IHC staining S-P kit (KIT-9710; MAIXIN Biology
Corporation, Fuzhou, China) was used to visualize antibody
binding on the slides. Counterstaining was performed with
hematoxylin. The IHC staining of Nedd4-1 in these speci-
mens was evaluated by two individuals under an Olympus
CX31 microscope (Olympus, Center Valley, PA).
Evaluation of immunostaining
A mean percentage of Nedd4-1 positive tumour cells
was determined in at least five areas at × 400 magnifica-
tions (50–250 cancer cells per area) and assigned from 0
to 100. The intensity of immunostaining was scored as
follows: weak, 1+, moderate, 2+; and intense, 3+. Theor-
etically, the percentage of Nedd4-1 positive tumor cells
and the staining intensity were multiplied to produce a
weighted score for each case: ranging from 0 (0% of cells
staining) to 300 (100% of the cells staining at 3+ inten-
sity). For convenience in reporting and statistical analysis,
the staining was classified as negative, weak, moderate
and strong. The cut-off points were based on the
scores: negative, 0; weak, <75; moderate, 75–150; and
intense, >150. The score <75 is defined as low expres-
sion, and >75 as high expression.
Cell culture and knockdown of Nedd4-1 by lentiviral
vector-loaded shRNA in gastric cancer cells
Gastric cancer cell lines AGS and N87 was purchased from
ATCC and maintained in Dulbecco's modified Eagle'smedium (DMEM) (Hi-Clone) plus 10% FBS at 37°C
with 5% CO2.
Lentiviral particle packaging was performed as following.
Briefly, the lentiviral shRNA plasmid was co-transfected
with psPAX2 (Addgene) and pMD2.G (Addgene) into
HEK293KT cells for 8 hrs. The viral particle-containing
medium was collected every 24 hours for three times after
transfection. The medium was centrifuged at 1000xg for
5 min to remove cell debris, and used for infecting the gas-
tric cancer cells in presence of 6 μg/ml polybrene. The in-
fected gastric cancer cells were selected with puromycin,
and the effect of Nedd4-1 knockdown was detected by im-
munoblotting the cell lysates with anti-Nedd4-1.
Preparation of cell lysates and immunoblotting
Cells were rinsed once with ice-cold PBS and lysed in
ice-cold Mammalian lysis buffer (40 mM Hepes (pH 7.4),
100 mM NaCl, 1% Triton X-100, 25 mM glycerol phos-
phate, 1 mM sodium orthovanadate, 1 mM EDTA, 10 μg/
ml aprotinin, and 10 μg/ml leupeptin) or RIPA buffer
(40 mM Hepes, pH 7.4, 1% Triton X-100, 0.5% Na-
deoxylcholate, 0.1% SDS, 100 mM NaCl, 1 mM EDTA,
25 mM β-glycerolphosphate, 1 mM Na-orthovanadate,
10 μg/ml leupeptin and aprotinin) as indicated. The cell
lysates were cleared by centrifugation at 13,000 rpm for
15 minutes. The cell lysates were denatured by addition of
sample buffer and boiled for 5 minutes, resolved by 8%-
14% SDS-PAGE, and then transferred to PVDF mem-
branes (millopore). The membranes were incubated with
primary antibodies 12 hrs at 4°C and HRP-conjugated sec-
ond antibodies for 3–5 hrs at 25°C. The protein bands
were detected by the chemiluminescence kit (Fuji).
Determination of cell proliferation, migration and
invasion of gastric cancer cells
(1) Determination of cell proliferation. The control or
the Nedd4-1 knockdown N87 cells were cultured in
DMEM with 10% FBS at 37°C plus 5% CO2 for indicated
times. The cells were trypsinized and counted under a
phase microscope with a hemocytometer. The cell count-
ing was repeated at least three times.
(2) Cell migration assay. Cell migration was deter-
mined by the transwell assay and the wound healing
assay. (i) The transwell assay. Cells grown in DMEM
with 10% FBS were trypsinized and resuspended in
DMEM with 10% FBS. 4 × 104 cells were gently added
to the upper compartment of Transwell (Corning).
DMEM with 10% FBS or EGF were added to the lower
compartment of Transwell. The cells were incubated in
the culture incubator at 37°C plus 5% CO2 for indicated
time. The remained cells on the upper side were gently
removed with cotton balls. The cells migrated from the
upper side to the lower side through the filter were fixed
by 5% glutaraldehyde for 10 minutes, then stained with
Sun et al. Molecular Cancer 2014, 13:248 Page 9 of 10
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stained cells on the lower side were counted under micro-
scope from 5 different randomly selected views. The cell
number averaged from the 5 microscopic views was used
as the migration cell number. The migration experiments
were repeated twice. (ii) The wound-healing assay.
8 × 105 cells were seeded on 6-well plates in DMEM
supplemented with 10% FBS. 16 hrs later, the cells
reached to about 80-90% confluence in a monolayer. A
pipette tip was used to make a straight scratch line in
the cell monolayer. The cells were incubated for indi-
cated times and treated as required. The experiments
were repeated at least three times.
(3) Cell invasion assay. The transwell top chamber
membrane was coated with 40 μl of 0.125 mg/ml
matrigel in PBS and incubated at 37°C for 5 hrs before
use. The gastric cancer AGS cells were trypsinized and
washed with PBS 1–2 times and resuspended in DMEM
at 5 × 105 cells/ml. Before loading the cells, the matrigel
layer was incubated in 300 μl of DMEM at 37°C for
30 min. The cells (200 μl in DMEM) were added to the
top of the matrigel layer. The bottom chamber of the
transwell was filled with 500 μl of DMEM plus 10% FBS.
The cell invasion was carried out at 37°C and 5% CO2 for
24 hrs. After the invasion was done, the cells in the
top chamber were removed by cotton balls. The cells
on the bottom side (invaded cells) of the membrane
were fixed with 4% paraformaldehyde at 25°C for
30 min and stained with 0.1% crystal violet solution at
25°C for 20 min. The stained cells were washed with
PBS three times and observed and photographed under
a phase microscope.
Statistical analysis
The association between clinicopathological variables and
Nedd4-1 status was tested using chi-square test. The out-
come of interest was mortality. Kaplan-Meier survival
analysis was conducted from post-surgery to death, strati-
fied by Nedd4-1 expression status, TNM stage, T category,
N category, tumor size, and differentiation, respectively.
Log-rank test was used to test each of above factors.
When analyzing association of Nedd4-1 expression with
cumulative survival, TNM stage IV patients (33 cases)
were excluded, because expression of Nedd4-1 in TNM
stage IV GCA tumor samples has no prognostic value.
The multivariate Cox proportional hazard model was used
to determine the association between Nedd4-1 status
and survival, controlling for tumor size, differentiation,
T category, N category and TNM stage. Hazard ratio
(HR) and 95% confidence interval (95% CI) were calcu-
lated for each factor. Interactions were also tested for
each pair of factors. P-value <0.05 was considered to
be statistically significant, and all analyses were conducted
using IBM SPSS software (IBM Corp, Armonk, NY).Additional file
Additional file 1: Characterization of the anti-Nedd4-1 antibody.
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